BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL. Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag 2012;8:377-84. [PMID: 23028230 DOI: 10.2147/TCRM.S33674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Marcellusi A, Bini C, Andreoni M, Antinori A, Mennini FS. Valutazione delle conseguenze epidemiologiche ed economiche generate dal ritardo di trattamento dei pazienti HIV-positivi causato dalla pandemia COVID-19. Glob Reg Health Technol Assess 2021;8:147-54. [PMID: 36627876 DOI: 10.33393/grhta.2021.2279] [Reference Citation Analysis]
2 Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clin Drug Investig 2016;36:377-87. [PMID: 26940802 DOI: 10.1007/s40261-016-0382-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Di Carlo P, Guadagnino G, Immordino P, Mazzola G, Colletti P, Alongi I, Adamoli L, Vitale F, Casuccio A. Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy. Patient Prefer Adherence 2016;10:919-27. [PMID: 27307712 DOI: 10.2147/PPA.S90456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tse WF, Yang W, Huang W. A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res 2015;7:431-9. [PMID: 26316787 DOI: 10.2147/CEOR.S85535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas 2015;6:53-60. [PMID: 25733942 DOI: 10.2147/PROM.S63586] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag 2014;10:9-15. [PMID: 24379676 DOI: 10.2147/TCRM.S49428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
7 Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res 2013;5:489-96. [PMID: 24124383 DOI: 10.2147/CEOR.S48246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]